MC
AXSM icon

Moors & Cabot’s Axsome Therapeutics AXSM Stock Holding History

Moors & Cabot’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$570K Hold
2,330
– – 0.02% 529
2026
Q1 		$394K Sell
2,330
-100
-4% -$17.3K 0.02% 612
2025
Q4 		$444K Buy
2,430
+50
+2% +$6.98K 0.02% 574
2025
Q3 		$289K Buy
2,380
+50
+2% +$5.63K 0.01% 685
2025
Q2 		$243K Buy
2,330
+100
+4% +$10.6K 0.01% 725
2025
Q1 		$260K Buy
+2,230
New +$254K 0.01% 689
2024
Q4 		– Sell
-2,230
Closed -$200K – 890
2024
Q3 		$200K Buy
+2,230
New +$195K 0.01% 804

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Moors & Cabot's AXSM Position: Q2 2026 in Review

Moors & Cabot held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 2,330 shares worth $570K. The position accounts for 0.02% of the portfolio, ranked #529.

Moors & Cabot first reported a position in AXSM in Q3 2024 and has held it in 7 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Moors & Cabot held 2,330 shares of Axsome Therapeutics worth $570K as of Q2 2026.
  • Moors & Cabot left its Axsome Therapeutics share count unchanged in Q2 2026.
  • Axsome Therapeutics made up 0.02% of Moors & Cabot's portfolio in Q2 2026, its #529 holding.
  • Moors & Cabot first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.